Payment overview · 2025
General Payments
$187.79
9 reported records · 7 companies
Healthcare provider profile · identity verified
Darron B Locke, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROARING SPRING, PA · NPI 1073507943
Verified facts
What the public records show
CMS Open Payments records show Darron B Locke, MD received $187.79 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.77 | 32.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.37 | 19.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.65 | 13.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.72 | 9.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.65 | 8.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.51 | 8.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.12 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $187.79 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $32.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
65 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
453 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 703 | 139 |
| Gabapentin | Gabapentin | 664 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 126 |
| Furosemide | Furosemide | 532 | 132 |
| Lisinopril | Lisinopril | 496 | 132 |
| Eliquis | Apixaban | 453 | 91 |
| Omeprazole | Omeprazole | 411 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 400 | 117 |
| Losartan Potassium | Losartan Potassium | 322 | 83 |
| Warfarin Sodium | Warfarin Sodium | 322 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 287 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 42 |
| Donepezil Hcl | Donepezil Hcl | 241 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 53 |
| Potassium Chloride | Potassium Chloride | 234 | 67 |
| Metformin Hcl | Metformin Hcl | 224 | 49 |
| Famotidine | Famotidine | 206 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 60 |
| Sertraline Hcl | Sertraline Hcl | 193 | 43 |
| Memantine Hcl | Memantine Hcl | 182 | 26 |
| Buspirone Hcl | Buspirone Hcl | 181 | 24 |
| Allopurinol | Allopurinol | 179 | 47 |
| Tramadol Hcl | Tramadol Hcl | 178 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 32 |
| Lorazepam | Lorazepam | 174 | 68 |
| Xarelto | Rivaroxaban | 170 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 22 |
| Mirtazapine | Mirtazapine | 148 | 27 |
| Trazodone Hcl | Trazodone Hcl | 141 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 139 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 138 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 38 |
| Jardiance | Empagliflozin | 131 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 28 |
| Carvedilol | Carvedilol | 103 | 32 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 101 | 37 |
| Prednisone | Prednisone | 98 | 65 |
| Alendronate Sodium | Alendronate Sodium | 96 | 21 |
| Celecoxib | Celecoxib | 95 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 22 |
| Finasteride | Finasteride | 86 | 18 |
| Myrbetriq | Mirabegron | 86 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 17 |
| Spironolactone | Spironolactone | 77 | 17 |
| Glipizide Er | Glipizide | 74 | 18 |
| Simvastatin | Simvastatin | 68 | 16 |
| Terazosin Hcl | Terazosin Hcl | 68 | 19 |
| Irbesartan | Irbesartan | 67 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 65 | 65 |
| Alprazolam | Alprazolam | 63 | 17 |
| Meloxicam | Meloxicam | 63 | 20 |
| Divalproex Sodium | Divalproex Sodium | 60 | suppressed |
| Ozempic | Semaglutide | 58 | 11 |
| Baclofen | Baclofen | 57 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | 20 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 56 | 17 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 15 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 11 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Atenolol | Atenolol | 49 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | 13 |
| Pregabalin | Pregabalin | 49 | 11 |
| Ezetimibe | Ezetimibe | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Latanoprost | Latanoprost | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 27 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 32 |
| Risperidone | Risperidone | 37 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 11 |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 17 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 20 |
| Topiramate | Topiramate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | 13 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | 11 |
| Morphine Sulfate | Morphine Sulfate | 15 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Lactulose | Lactulose | 14 | suppressed |
| Levofloxacin-D5w | Levofloxacin In Dextrose 5 % | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fosamax Plus D | Alendronate Sodium/Vitamin D3 | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $187.79 · 9 records | ABBVIE INC. | FREESTYLE LIBRE 3, LEQVIO, NURTEC ODT, Ozempic, REXULTI, RINVOQ, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error